English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Tianjin CanSino Biotech Raises $10 Million from Lilly Asia Ventures

Sep. 16, 2013

Tianjin CanSino Biotechnology announced on Sept. 16, 2013 that it has received a $10 million strategic investment from Lilly Asia Ventures, a venture capital arm of Eli Lilly. CanSio Biotech Inc. was founded in the Tianjin Economic and Technological Development Area (TEDA) in 2009 and specializes in R&D and manufacture of human vaccines. The capital raised this time will be used for R&D, clinical research and early stage commercialization of DTcP (diphtheria, tetanus and component pertussis)-based combo vaccines and several other novel vaccines.